Blog Posts
FDA

Zanidatamab is approved by US FDA based off Herizon BTC01

Oncology Brothers shared a post on X:

“Zanidatamab (bispecific antibody against Her2) now US FDA approved for unresectable/metastatic HER2+ biliary tract cancer based off HerizonBTC01 – Single arm Ph2B study, 20 mg/kg IV Q2W – mDoR 14.9mos – mOS 15.5mos – AEs: Diarrhea, EF.”

Zanidatamab

Zanidatamab

More posts featuring Oncology Brothers.

antibody biliary tract Biliary tract cancer cancer diarrhea HER2 HerizonBTC01 metastatic OncoDaily Oncology Oncology Brothers US FDA Zanidatamab